ZNF131 Antibody

Role in Cancer Biology

ZNF131 is overexpressed in non-small cell lung cancer (NSCLC) and correlates with advanced TNM stages, lymph node metastasis, and poor prognosis. Key findings include:

• Transcriptional Activation of RAD51: ZNF131 binds the RAD51 promoter (-668 to -403 bp), enhancing homologous recombination repair (HR) and conferring resistance to radiotherapy and chemotherapy .

• Interaction with BACH1: The ZNF131-BACH1 complex stabilizes both proteins by inhibiting CUL3-mediated ubiquitination, amplifying RAD51-dependent HR and therapy resistance .

• Therapeutic Targeting: Desoxyrhaponticin suppresses ZNF131-RAD51 axis activity, sensitizing NSCLC cells to treatment .

Immune Cell Regulation

• T-Cell Development: ZNF131 is essential for DN-to-DP thymocyte differentiation by suppressing p21 Cip1, a cyclin-dependent kinase inhibitor. Knockout models show blocked T-cell proliferation and impaired immune responses .

Pathway Regulation

• Downstream Targets: RAD51, p21 Cip1, and estrogen receptor (ESR1) .

• Functional Domains:

  • BTB Domain: Mediates protein-protein interactions (e.g., BACH1 binding) .

  • Zinc Finger Domains: Direct DNA binding at promoter regions .

Validation and Quality Control

ZNF131 antibodies are rigorously validated across platforms:

• Western Blot: Detects ~71 kDa band in NSCLC cell lines (H1299, A549) .

• Immunofluorescence: Nuclear localization in HeLa and NSCLC cells .

• Protein Arrays: Specificity confirmed via 364 recombinant protein screens .